StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities research analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report issued on Thursday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets lowered their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY stock opened at $0.65 on Thursday. The company’s fifty day simple moving average is $0.63 and its 200-day simple moving average is $0.61. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $9.08. The company has a market cap of $3.18 million, a PE ratio of -0.01 and a beta of 0.67.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.